Strategic Pharma Partnerships BreezeBio's multi-year collaboration with Genentech demonstrates strong pharma interest in their delivery platform, signaling potential for expanded licensing, co-development, or joint programs with large biotech partners to accelerate autoimmune and oncology initiatives.

Autoimmune Collaboration The lead program BRZ-101 advances toward IND-enabling studies for type 1 diabetes, creating near-term collaboration opportunities for autoimmune indications, including licensing the NanoGalaxy platform or co-developing next-generation delivery approaches with pharma and CRO partners.

Platform Licensing Opportunities The NanoGalaxy platform enables targeted non-viral delivery to immune cells and select tissues, opening doors for contract R&D, platform licensing, or collaboration with pharma companies seeking to de-risk gene therapy programs in autoimmune, oncology, cardiopulmonary, and CNS spaces.

Growth Capital Leverage A $60M Series B and mid-range revenue indicate solid growth and financial runway to support deal-making, milestone-based partnerships, and scalable manufacturing arrangements for nanoparticle production and clinical-grade materials.

Regional Biotech Hub Based in South San Francisco, BreezeBio sits in a dense ecosystem with proximity to Genentech and other biotech leaders, enabling rapid partnership formation with CROs, CMOs, and potential clinical and manufacturing collaborators to advance IND-enabling studies and commercialization.